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Proposal  for  a 
COUNCIL  DECISION 
adopting  a  specific and  technological  development  programme 
In  the  field of  Biomedicine  and  Health 
(1990-94) 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the  Treaty  establ lshlng  the  European  Economic 
Community,  and  In  particular Article  130q  (2)  thereof, 
Having  regard  to  the  prooosal  from  the  Commlsslon,<1> 
In  cooperation with  the  European  Pari lament,C2) 
Having  regard  to  the opinion of  the  Economic  and  Social  Commlttee,<3> 
(1)  OJ  No  C 
(2)  OJ  No  C 
(3)  OJ  No  C - 3  -
Whereas  by  Its  Decision  90/221/Euratom,  EEc<4>,  the  Council  adopted  a 
third  framework  programme  for  Community  activities  In  the  field  of 
research  and  technological  development  (1990-94),  specifying  Inter  alIa 
the activities  to be  pursued  for  contributing  to  the  development  of  the 
European  potential  for  understanding  and  expoltlng  the  properties  and 
structures of  I lvlng  matter;  whereas  this  Decision  should  be  taken  In 
the  light  of  the  grounds  set out  In  the  preamble  to  that  Decision; 
Whereas  Article  130k  of  the  Treaty  stipulates  that  the  framework 
programme  Is  to  be  Implemented  through  specific  programmes  de-veloped 
within each  activity; 
Whereas  an  estimate should  be  made  of  the  amount  of  Community  financial 
resources  needed  to  carry  out  this  specific  programme;  whereas  the 
definitive  amounts  will  be  fixed  by  the  budgetary  authority  In  line 
with  the  financial  perspectives  covering  the  period  1988  1~92 
Included  In  the  Interinstitutional  Agreement  of  29  June  1988(5)  and 
with  any  future  financial  perspectives covering  the  period  1993- 1994; 
Whereas,  pursuant 
90/221/Euratom,  EEC, 
framework  programme 
to  Article  4  and  Annex  of  Decision 
the  amount  deemed  necessary  for  the  whole 
Includes  an  amount  of  57  million  ecus  for  the 
centralized dissemination  and  exploitation of  results,  to  be  divided  up 
In  proportion  to  the  amount  envisaged  for  each  activity;  whereas  In 
view  of  the  Importance  of  this  specific  programme  within  the  "Life 
Sciences  and  Technologies"  action  the  estimate  of  the  financial 
resources  needed  by  this  programme  Is  to  be  reduced  by  1.33  million 
ecus,  which  amount  Is  to  be  allocated  to  the  centralized activities,  In 
order  to  comply  with  the  second  sentence  of  Article  130p  (2)  of  the 
Treaty; 
(4)  OJ  No  L 117,  8.5.1990,  p.28. 
(5)  OJ  No  L 185,  15.7.1988,  p.33. - 4  -
Whereas  this  programme  must  be  Implemented  by  the  Commission;  whereas 
to  help  accomplish  this,  the  Member  States  are  bound,  pursuant  to 
Article  5  of  the  Treaty,  to  facilitate  the  achievement  of  Its  tasks 
where  necessary,  notably  within  a  committee; 
Whereas  this programme  must  be  Implemented  essentially  by  the  selection 
of  research  and  development  projects  to  enable  them  to  benefIt  from 
Community  participation;  whereas  the  Commission  should  encourage  the 
submission  of  such  projects  by  the  usual  means  of  pub I lshlng  cal Is  for 
proposals  In  the  Official  Journal;  whereas  a  special  procedure  should 
also  be  devised  so  as  to  maintain  a  degree  of  flexlbl I lty  enabling  the 
Commission,  In  the  face  of  the  continuous  evolution  and  gradual 
acceleration of  technological  progress,  also  to  take  Into  consideration 
spontaneous  proposals consistent  with  the objectives of  the  programme; 
Whereas  the  projects  to  be  carr led  out  under  the  programme  must  be 
selected with  special  attention  to  the  principle of  economic  and  social 
cohesion  In  the  Community,  the  transnational  nature of  the  projects and 
the  support  to  be  given  to  smal I  and  medium-sized  enterprises; 
Whereas  It  Is only  In  the  I lght  of  experience  gathered  In  the  course of 
this  programme  that  the  Commission  will  be  ?ole  to  propose  and  the 
Council  to  adopt  supplementary  programmes  by  t-t:vlng  recourse  to  the 
means  provided  for  In  Articles  1301,  130m  or  130o  of  the  Treaty,  If 
they  contribute  to  the  achievement  of  the  programme's  obJectlvas,  In 
accordance  with  the  option  made  aval lable  by  Article  2(2)  of  Decision 
90/221/Euratom,  EEC; 
Whereas,  In  accordance  with  Article  130g  of  the  Tr~1ty,  the  Community's 
activities  aimed  at  strengthening  the  scientific  and  technological 
basis  of  European  Industry  and  encouraging  It  to  become  more 
competitive  Include  promoting  cooperation on  research  and  technological 
development  with  third  countries  and  International  organizations; 
whereas  such  cooperation  rnay  prove  particularly  b3neflclal  for  the 
development  of  this  orogran~e; - 5  -
Whereas  It  Is  necessary,  as  Annex  II  to  Decision  90/221/Euratom,  E£C, 
provides  to  contribute  to  Improving  the  efficacy  of  medical  and  health 
research  and  development  In  the  Member  States,  In  particular  by  better 
coordination  of  the  Member  States'  research  and  development  activities 
and  application  of  th£1  results  through  Community  cooperation  and  a 
pool lng  of  resources; 
Yli1~reas  the  Scientific  and  Technical  Research  Committee  (CREST)  has 
been  consu I ted, - 6  -
HAS  ADOPTED  THIS  DECISION: 
Article  1 
A  sp~clflc  research  and  technological  development  programme  for  the 
European  Economic  Community  In  the  field  of  biomedicine  and  health,  as 
defined  In  Annex  I,  Is  hereby  adopted  for  a  period  of  five  years  as 
from  1  January  1990. 
Article  2 
1.  The  Community  funds  estimated  as  necessary  for  the  execution of  the 
programme  under  this  Decision  amount  to  133  ml  I I lon  ecus.  Of  this 
amount  1.33 ml  II lon  ecus  Is  drawn  for  the  central lzed  dissemination 
and  exploitation  of  results.  The  amount  thus  reduced  to 
131.67 million  ecus  Includes  staff  costs  which  may  not  exceed  4%. 
An  Indicative  breakdown  of  expenditure  Is  set  out  In  Annex  I I. 
2.  Should  the  Council  take  a  decision  In  Implementation  of  Article 
1(4)  of  Decision  90/221/Euratom,  EEC,  this  Decision  shal 1  be 
adapted  to  take  account  of  the  abovementioned  decision. 
3.  The  budgetary  authority  shall  decide  on  the  appropriations 
aval lable  for  each  financial  year. 
Article  3 
Rules  for  the  Implementation  of  the  programme  are  set  out  In  Annex  :11. 
Article  4 
The1  rate of  the  Cor~.~·.J.nlty  financial  contribution  shall  be  laid  down  In 
accordance with  Annex  IV  to  Decision  90/221/Euratom,  EEC. - 7  -
Article 5 
1.  During  1992  the  Commission  shall  review  the  programme  anti  address  a 
report  on  the  results of  the  review  to  the council  and  the  European 
Parliament,  iogether  with  proposals  for  any  necessary  changes. 
2.  At  the  end  of  the  programme  the  Commission  shal I  assess  the  results 
obtained.  It  shall  address  a  report  thereon  to  the  Councl I  and  the 
European  Pari lament. 
3.  The  reports  shal I  be  drawn  up  having  regard  to  the  objectives  set 
out  In  Annex  I  to  this Decision  and  In  accordance  with  Article  2(4) 
of  Decision  90/221/Euratom,  EEC. 
Article 6 
1.  The  Commission  shal I  be  responsible  for  the  execution  of  the 
programme.  It  shal I  be  ass  ~ted  by  a  committee,  hereinafter 
referred  to  as  "the  Committee'·,  composed  of  representatives  of  the 
Member  States and  chaired  by  a  representative of  the  commission. 
2.  The  contracts  concluded  by  the  Commission  shal I  govern  the  rights 
and  obi lga\lons  of  each  party,  Including  the  procedures  for 
disseminating,  protecting  and  exploiting  the  research  results,  In 
accordance  wl th  the  arrange~ents  adopted  pursuant  to  the  second 
paragraph of Article  130k  of  the  Treaty. 
3.  A work  programme  for  each  year  shal I  be  drawn  up  and  updated  where 
necessary.  It  sha II  set  out  the  deta lied  objectIves  and  types  of 
proJects  to  be  undertaken,  and  the  f I  nanc I  a I  arrangements  to  be 
made  for  them.  The  Commission  shal I  make  cal Is  for  proposals  for 
proJects on  the basis of  the  annual  work  programmes. - 8  -
Article 7 
1.  In  the  cases  envisaged  In  Article  8(1),  the  Commission 
representative  shal I  submit  to  the  Committee  a  draft  of  the 
measuree  to  be  taken.  The  Committee  shall  deliver  Its  opinion  on 
the  draft  within  a  time  limit  which  the  chairman  may  set  according 
to  the  urgency  of  the  matter.  The  opinion  shall  be  delivered  by 
qualified majority  as  provided  for  In  Article  148(2)  of  the  Treaty 
In  the  case  of  decisions  which  the  Council  Is  required  to  adopt  on 
a  proposal  from  the  Commission.  The  votes  of  the  Member  States' 
representatives  within  the  Committee  shal I  be  weighted  In  the 
manner  set out  In  that  Article.  The  chairman  shal I  not  vote. 
2.  The  Commission  shal I  adopt  the  measures  envisaged  where  they  are  In 
accordance  with  the  Committee's  opinion. 
3.  If  the  measures  envisaged  are  not  In  accordance  with  the 
Committee's  opinion,  or  If  no  opinion  Is  del lvered,  the  Commission 
shall  forthwith  submit  to  the  Council  a  proposal  relating  to  the 
measures  to  be  taken.  The  Councl 1  shal 1  act  by  a  qual I fled 
majority. 
4.  If  the  Council  has  not  acted  within  one  month  of  submission  of  the 
proposal,  the  proposed  measures  shal I  be  adopted  by  the  Commission. 
Article 8 
1.  The  procedure  laid  down  In  Article 7  shal I  apply  to: 
the  preparation and  updating of  the  work  programmes  referred  to 
In  Article 6(3); 
evaluation of  the  projects referred  to  In  point  2 of  Annex  111, 
as  well  as  the  estimated  amount  of  the  Community's  financial 
contribution  when  these  projects  are  submitted  through  the 
ordinary  procedure  referred  to  In  point  4  of  Annex  I I I  and  the 
ab~vementloned amount  Is  more  than  5  ml  I I lon  ecus; - 9  -
evaluation  of  all  projects  submitted  through  the  exceptional 
procedure  referred  to  In  point  4  of  Annex  Ill,  as  well  as  the 
estimated  amount  of  the  Community's  financial  contribution; 
measures  for  evaluating  the  programme. 
2.  The  CommIssIon  may  consu It  the  CommIt tee  on  any  matter  fa Ill ng 
within  the  scope of  the  programme. 
3.  The  Commission  shal I  Inform  the  Committee  with  regard  to; 
the  progress of  the  programme; 
planned  cal Is  for  proposals,  referred  to  In  Article 6  (3); 
projects,  referred  to  In  point  2  of  Annex  I I I,  submitted 
through  the  ordinary  procedure,  for  which  the  Community 
contribution  Is  less  than  5  million  ecus,  and  the  results  of 
their  evaluation; 
accompanying  measures,  referred  to  In  point  2 of  Annex  11  I; 
c~ncerted actions,  referred  to  In  point  2 of  Annex  I I I. 
Article 9 
In  Implementing  this  programme,  supplementary  programmes  within  the 
meaning  of  Article  1301,  participation  within  the  meaning  of  Article 
130m  and  Joint  undertakings  or  any  other  structures  within  the  meaning 
of  Article  130o  of  the  Treaty  may  also  be  decided  on  as  the  need 
arises. - 10  -
Article  10 
Where  cooperation  with  third  countries  and  lnternat,onal  organisations 
aiming  at  achieving  the  obJectives  of  this  programme  requires  legal 
undertakings  between  the  C~~munlty and  the  third parties concerned,  the 
Commission  shal I  be  authorized  to negotiate,  In  accordance  with  Article 
130n  of  the  Treaty,  International  agreements  laying  down  the  terms  of 
such  cooperation. 
Decisions  on  the  conclusion  of  such  agreements  shall  be  adopted  In 
accordance  with  the  procedure  referred  to  In  Article  130q  (2)  of  the 
Treaty. 
Article  11 
This  Decision  Is  addressed  to  the  Member  States. 
Done  at  .........  ,  ........  .  For  the  Counc II, 
The  Presldant - 1.1  -
Annex  I 
SCIENTIFIC AND TECHNICAL OBJECilVES AND  CONTENT 
This specific programme fully reflects the approach embodied in the Third Framework 
Programme  in  terms  of the  scientific  and  technical  goals  and  the  underlying  aims 
which it pursues. 
Paragraph 4C of Annex li of the Framework Programme forms  an integral part of the 
present specific  programme. 
Close  coordination  will  be  maintained  with  other  relev<mt  research  programmes, 
including  "Life  Sciences  and  Technologies  for  Developing  Countries",  "Telematics 
Systems  - Health Care",  and "Medical  Research
11  under the European Coal  and Steel 
Community Treaty. 
The principle of subsidiarity will be applied to the maximum, through encouraging the 
harmonization  of  approaches  and  methodologies  used  in  different  national 
programmes. The projects  themselves will  have a  European dimension arising from 
their polycentric execution based on research networks. Harmonized methods, specified 
in the relevant protocols, will ensure that the data resulting from the projects carried 
out throughout the Community can be statistically analysed and coherently exploited 
anywhere in the Community. 
Prenom1ative research will be developed whenever needed for serving patients' needs 
and for the completion of the Internal Market. 
The  following  presents  an analytical  description  of the  content of the  programme, 
based on and taking account of the above elements. Area  1. 
- 12  -
Harmonization  of  methodologies  and  protocols  in  epidemiological, 
biological and clinical research 
The  essential  features  of  this  area  are  outlined  below:Testing  of  drugs  will  be 
conducted  through  the  development  of networks,  enabling  both  the  collection  of 
clinical and epidemiological data and the monitoring and surveillance of prescriptions 
and of adverse drug reactions. 
Screening for  risk factors  will  be  covered,  especially in the  context of occupational 
health.  Examples  of risk  factors  at  work  include  shiftwork,  new technology in the 
office and occupational health risks  in health care workers.  Safety in laboratories is 
of particular  importance.  Related  topics  include  audit  in  occupational  health  and 
ethical problems. 
In biomedical technology, research will  be  directed towards the development of new 
coherent diagnostic procedures, such as medical imaging techniques.  In the biomedical 
engineering  area,  the  aim  is  to  restore  function  as  completely  as  possible  to  the 
handicapped, particularly by developing new biomaterials for use in prostheses, tissue 
replacements and artificial  organs.  Methods of monitoring the effects  of treatment, 
and consequent restoration of function,  will also be developed. 
Harmonization  of protocols  and  approaches  as  regards  the  management  of health 
services will be emphasized. - 13  -
Area  2.  Applications to diseases of great socio-economic impact 
Five  economically  ami  socially  significant  disease  groupmgs  will  be  considered,  as 
described below: 
AIDS 
The research will take into account the activities already developed by the Community 
and will be spread over five  sectors  : 
The  disease  prevention sector will  concentrate on specific  epidemiological  projects, 
studies  of primary  and  secondary  prevention,  assessment  of preventive  strategies, 
behavioural research and forecasting,  using inter alia centres or facilities with unique 
characteristics. 
The  fundamental  research  sector will  concentrate  on AIDS  viruses,  host  response, 
pathogenesis and animal studies. 
The clinical research sector will concentrate on clinical trials,  clinical manifestations, 
supJJ'ort  of clinical centres and support of national coordination, e.g.  by  establishing 
a  network  of Clinical  AIDS  Reference  Centres  and  other  relevant  groups.  This 
immediately  sensitive  part  of  the  programme  will  be  given  a  special  priority. 
Prenormative  research  will  be  included,  with  development  of  new  drugs  being 
emphasized. 
The development of a European Vaccine against AIDS  (EVA)  will be actively pursued. 
Its objective is the promotion of collaborative research by the provision of high-quality 
reagents for investigations of the immune response to lentivim:;e§ and the induction 
of  prot~ctive  immunity.  A  centralized  laboratory  facility  will  be  provided,  and 
arrangements will  be  made  for  industrial  and  academic  laboratories  to  produce  to 
agreed specifications  required amounts  of antigens,  sera,  cells  and other materials; 
!he centralized facility will  be  responsible for  assaying  the materials,  together with 
their adequate storage and distribution. - 14  -
Testing methods for Antiviral Drugs  in  AIDS  Management  (ADAM),  the most recent 
domain of research,  will  be developed.  Primary screening capacity will  be  increased 
by  introducing  additional  primary  screening  methods;  further  research  will  ~" 
undertaken on the mode  of action of promising compounds,  and consideration may 
be given to ways of scaling up their production. 
Cancer 
Research will concentrate on improved methodologies involving differing combinations 
of surgery,  radiotherapy,  chemotherapy and  immunotherapy,  and  their subsequent 
harmonization.  Loca~ appror.ches involving surgery and radiotherapy will  be studied 
vis-a-vis  improved methods of removing all  visible  tumour tissue,  aiming to leave  a 
minimal  tumour burden with resulting maximization of the effects  of new systemic 
treatments as they become available. More effective methods of local control, as  well 
as  of systemic  treatments, will  be  developed  in order to achieve  rapid  improvement 
in overall survival. Selectivity of radiotherapy will be further improved, e.g. using light 
ion  therapy  and  Boron  neutron  capture  therapy  (BNCT),  aiming  at  an improved 
survival ratte. 
Epidemiology and f  .. mdamental research on genomic and phenotypic changes in cancer 
cells  (invasion  and  metastasis)  and  i nmune  surveillance  will  be  extended.  Priority 
supp01t activities will include  the ii  r  ,provement of European tumour cell  and tissue 
bank resources, and the development of the scientific basis for common guidelines for 
anti-cancer dmg screening. 
Cardiovas:cular Disease 
The  various  forms  of heart  and  circulatory  disease  will  be  studied,  focusing  on 
research where coherent broadly-based clinical surveys are most useful; this includes 
correlation  between  life  style,  nutrition,  and  the  incidence  and  development  of 
cardiovascular disturbances, the effects of prophylactic and therapeutic measures, the 
development of new regimens for  the treatment and the tes-ting of drugs. - 15  -
Mental Illness and Neurological DisorrJers,  and Mental Handicap 
A comparative analysis  of aetio-pathogenetic  factors  and  conditions  relative  to  the 
incidence  of mental  illness  in  widely  different  psycho-social  environments  will  be 
carried out in order to obtain an insight into the responsible  mechanisms.  Systems 
for the handling and treatment of patients will  be compared in order to identify the 
most effective.  A coherent, multidisplinary approach to  the study of central nervous 
system malfunctioning common to mental illness  and neurological disorders  will  be 
pursued. Multiple sclerosis and Parkinson's disease are examples. 
A  comparative  study  of  the  handling  of the  mentally  handicapped  and  of  their 
rehabilitation will  be  carried  out.  The  approach will  be  broad  and  comprehensive, 
ranging from the molecular to  the socio-economic aspects. 
Ageing, and Age-Related Health  Problems and Disabilities 
Comparative research on perinatal and paediatric illnesses and on the effectiveness of 
prophylactic and therapeutic measures will  be  carrie<l  0ut. 
A concerted approach to  the study of ageing,  with emphasis on the clinical aspects, 
will be pursued in order to identify, on a large-scale factual basis,  essential elements 
in the maintenance of the quality of life  in the aged,  in preventing or delaying the 
functional decline of the individual, and in reducing costs to society. Special attention 
will be given to the effects of the environment on health, especially on people in the 
more  vulnerable  ages;  this  will  be  pursued  in  close  liason  with  research  on 
environmental protection. - 16  -
Area  3.  Human Genome Analysis 
This  research will  be  developed  towards  the  completion  and  the  integration of the 
genetic and physical maps.  In  addition,  the study of the genetic basis  for  biological 
fur;  ~ions will  be  pursued,  as  well  as  the  setting-up of a  consortium  to  sequence  a 
portion of the genome of major biological interest  (e.g.  the  portion coding for  the 
Human Lymphocyte Antigen system). 
Emphasis will  be  placed on medical applications which contribute to  the well-being 
of patients:  in particular, on understanding the genetic component of multifactorial 
conditions  such  as  Alzheimer's  disease,  and  on  developing  methods  intended  to 
improve  therapies.  Links  will  be  maintained  with  appropriate  international 
organizations or forums  (e.g.  HUGO,  the Human Genome Organization),  ?.s  well  as 
with  research  actions  in  non-member  states  using  similar  or  complementary 
approaches.  The  Community  programme  is  characterized  by  its  emphasis  on  gene 
mapping and on the use of information resulting from  the analysis of other species' 
genomes. 
Particular attention and caution will be given to the ethical, social and legal aspects 
of this work, especially to those which may be linked to possible misuses of research 
findings.  No  research  modifying,  or seeking  to  modify,  the  genetic  constitution of 
human beings  by alteration  of germ  cells  or of any stage  of embryo  development 
which  may  make  these  alterations  hereditary  will  be  carried  out  under  this 
programme. - 17  -
INDICATIVE  BREAKDOWN  OF  EXPENDITURES 
in %,  for the period 1990-1994 
Area 1. 
Area 2. 
Area 3. 
Harmonization of methodologies and protocols in 
epidemiological,  biological and clinical research 
Applications  to  diseases of great 
socio-economic impact 
Human Genome Analysis 
Annex  II 
20- 25 
45 -so 
30- 35 
The breakdown between different areas does not exclude the possibility that projects 
could cover several areas. - 18  -
Annex  III 
Rules  for  l~plementlng the  Programme 
and  Activities  for  Dissemination  and  Exploitation of  the  Results 
1.  The  Commission  shall  Implement  the  programme  on  the  basis  of  the 
scientific and  technical  content  described  In  Annex  I. 
2.  The  rules  for  Implementing  the  programme,  referred  to  In  Article  3, 
comprise  research  and  technological  development  projects, 
accompanying  measures  and  concerted actions. 
The  projects  shal I  be  the  subject  of  shared-cost  research  and 
technological  development  ~ontracts. 
The  accompanying  measures  consist  of  applying  the  means  to  ensure 
proper  technical  execution,  management  and  evaluation  of  the 
programme,  as  well  as  adequate  dissemination  and  accesslbl I lty  of 
the  resu Its,  and  coordInatIon,  traInIng  and  consc lousness-ra IsIng 
of  the  participants  In  the  programme. 
The  concerted  actions  are  those  defined  In  the  Financial 
Regulation. 
3.  The  participants  In  the  projects  must  be  natural  or  legal  persons 
establ lshed  In  the  Community,  such  as  universities,  research 
organizations  and  Industrial  firms,  Including  small  and  medium-
sized  enterprises,  or  associations  thereof,  In  particular  European 
Economic  Interest  Groupings  (EEIGs). 
Natural  or  legal  persons  establ lshed  In  countries  which  have 
concluded  agreements  with  the  Community  foreseeing  scientific  and 
techn 1  ca 1  research,  may,  based  on  the  crIterIon  of  mutua I 
advantage,  take  part  In  the  projects  undertaken  In  the  context  of 
this  programme.  The  contracting  parties  under  such  arrangements 
shall  not  benefit  from  Community  funding.  They  shal I  contribute  to 
the general  administrative costs. - 19  -
4.  The  choice  of  projects  shall  be  carried  out  according  to  the 
following  order  of  priority,  the  first  method  being  the  rule,  the 
second  the  exception: 
The  participants  In  the  projects  shal I  be  selected on  the  basis  of 
the  ordinary  procedure  of  cal Is  for  proposals  referred  to  In 
Article 6  (3)  and  published  In  the Official  Journal  of  the  European 
Communities. 
The  Commission  may  also  accept  proposals  according  to  an 
except lona I  procedure  and  under  the  cond 1  t Ions  ment loned  be low. 
when  they  make  a  particularly  promising  and  significant 
contribution  as  regards  the  original lty  of  the  theme  proposed,  the 
novelty  of  the  scientific  and  technical  approach  and  the 
methodology  of  execution,  also  taking  Into  account  the  particular 
nature of  the  proposers. 
A  favourable  technical  evaluation  of  such  proposals  shall  not  by 
Itself  be  a  sufficient  Justification  for  accepting  a  proJect;  this 
exceptional  procedure  may  only  apply  after  verification  that  the 
nature  of  the  project,  as  defined  above,  does  not  Justify  the  use 
of  the  no~mal  procedure  for  cal Is  for  proposals. 
The  except lona I  procedure  must  be  comp I  eted  before  the  ordInary 
procedure  In  such  a  way  that  the  aval !able  amount  for  the 
Community's  financial  participation  In  projects  reta'lned  by  the 
ordinary  procedure  can  be  determined  precisely.  The  closing  date 
for  the  exceptional  procedure  shall  be  published  each  year  In  the 
Official  Journal. 
The  amount  of  the  financial  participation of  the  Community  for  al 1 
the  projects  retained  by  the  exceptional  procedure  wl  II  be  decided 
each  year,  In  relation  to  the  projects  selected  according  to 
particularly  strict  criteria  of  excellence.  In  any  case,  this 
amount  may  not  exceed  15%;  It  may  be  revised each  year  In  the  1  lght 
of  experience. - 20  -
The  Commission  shal I  draw  up  a  vade  mecum  setting out  al 1  the  rules 
applicable  to  this exceptional  procedure  in  order  to guarantee  ful I 
transparency. 
5.  The  projects  must  Involve  at  least  two  mutual !y  Independent 
partners establ lshed  In  different  Member  States. 
6.  The  Commission  may  encourage  the  part lei pants  to  form  a  European 
Economic  Interest  Grouping  (EEIG)  or  make  other  arrangements  for 
carrying  out  projects,  such  as  those  on  a  large  scale,  permitting 
decentralized  management  adapted  to  the  specific  reQuirements  of 
the  project. 
7.  The  knowledge  acQuired  during  the  course  of  the  projects  shal I  be 
disseminated  on  the  one  hand  within  the  specific  programme  and  on 
the  other  hand  by  means  of  a  central lzed  activity,  pursuant  to  the 
decision  referred  to  In  the  third  paragraph  of  Article  4  In 
Decision  90/221/Euratom,  EEC. 21
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FINANCIAL  STATEMENT 
1.  BUDGET I-lEADlNG AND 1Til£ 
Part  B of the general budget 
Subsection 6,  hem 6223 
Specific programme of Community RTD activities in the field of Biomedical and Health  ._ 
Research ( 1990-1994L 
2.  LEGAL  BASE 
Article  130 Q(2) of the Treaty. 
3.  OBJECfiVES AND DESCRIPTION 
See Annex I of the proposal. 
4.  FINANClAL  IMPUCATlONS 
Amounts deemed necessary in  MIO  ECU: 
Programme implementation 
Centralized action for  dissemination and exploitation 
TOTAL 
131.67 
1.33 
133.00 
The  indicative  operational  breakdovm of the  131.67  M£0  ECU  for  the  programme 
implemenration is  given in  Annex  II  of the proposal. 22
•  ~  I  •  r  '  I  ~  \  '  •  '  I  o  •'  I  \,  I  o  I  ';  •  •  •  :  '  I  >  ,: 
23 
lndi<~tive multiannual schedule (in MlO  ECU) 
CO<rrni ·tments 
Paymt'nts 
1990  1991 
25 
7 
1992 
24. so 
17.92 
1993 
59 
29 
1994( 1) 
23.17 
77.75 
TOTAL 
131.67 
131.67 
The  definitive  yearly  amounts  will  be  determined  by  the  budgetary  authority  in 
accordance with the financial  perspectives for  the period 1990-1992 (annexed to the 
lnrerinstitutional  Agreement  of  29  June  1984)  and  with  subsequent  financial 
perspectives which may be adopted for  1993 and  1994. 
5.  STAFF AND ADM£N£STRAT!VE  EXPENDITURE 
[n  addition  to  the  principal means of action which are contracts  (Annex  [[[), 
the  above  amounts  include  programme-related  staff  and  administrative 
expenditure estimated at no  more than 13  M£0  ECU. 
The expenditure on staff vvill  nor exceed 4% of the amount deemed necessary 
for the  programme implementation. This  implies  a  maximum of 18 statutory 
posts (A,  B and/or C)  at any given time during the life of the programme. The 
infrastructure costs  related  to  statutory staff will  be  borne  by  P3rt  A of the 
budget. 
( 1)  for the r  ymenr  appropriarions:  1994 and  beyond 23
24 
6.  lMPUCATlONS FOR HEVENUE 
The  contdbutions  by  third  country  contractors  towards  the  cost  of 
administration of the programme will  be  reused pursuant to  articles 27.2 and 
96 of the  Financial  Regulation(2). 
7.  TYPES  OF  CONTROL 
Control will  be  exercised  by  : 
- the Programme Management Committee (scientific control) 
- the services of the DG  responsible for  the execution of the programme, 
possibly assisted  by  independent experts 
- the Commission's  Financial Controller 
In accordance with Article 2 of the Financial Regulation(2), the use of appropriations 
will  be  subject  to  analyses  of 12osr -effectiveness  and  the  realization  of quantified 
objectives will  be  monitored. 
External  audit may be  earned our  by  the Court of Auditors  in  accordance  with the 
Treaty. 
(2)  Financial  Regulation  of 21  December  1977,  as  last  amended  by  Regulation 
610/90 of March  1  990 24 25 
SrATEMENT OF IMPACr ON COMPETITIVENESS AND EMPLOYMENT 
1.  The main reason for  introducing the measure 
The programme aims to contribute to  improving the effectiveness of research and 
development in medicine and health in  the  Member States, in particular through 
better co-ordination of their research and development activities,  to applying their 
findings  through  Community  co-operation  and  to  using  available  resources  in 
common. 
This  pre-competitive and mainly concerted action programme seeks to add to  the 
sum of basic and clinical knowledge, and then to  make publicly available all  new 
information as  early,  as  often and  as  extensively  as  possible.  Businesses  of any 
size  will  thus have  the opportunity to  benefit from  their developing any matters 
of their own choice mising from  such Community research activities. 
2.  Features of the businesses in question 
The  businesses can be  of any nature or size,  including small and  medium-sized 
ones, and their interests may range from items of medical equipment and supplies 
through to pharmaceutical agents such as  new or improved vaccines or drugs. 
3.  Obligations imposed directly on businesses 
The  same  obligations  are  imposed  on  all  institutions  participating  m  the 
programme  including:  conformity  of the  proposed  research  with  the  technical 
annex  of the  project,  transnational  cooperation,  free  site-access  to  Commission 
agents,  participation  in  seminars  and  meetings  of contractors  organized  by  the 
Commission, and annual reports of activities and results. 25 26 
4.  Indirect  obligations  likely  to  be  imposed  on  businesses  by  national,  regional  or 
local  authorities 
No  such  obligations  are  foreseen  following  the  implementation of this  Council 
decision. 
5.  Special provisions in  respect of small and medium-sized entemrises 
None,  as  mentioned earlier. 
6.  Likely effects on: 
a.  The competitiveness of business 
As the programme is  aimed at pre-competitive research, not leading directly to 
new commercial products or processes, there will be no immediate effect on the 
competitiveness of business. It  \'l'ill  nevertheless contribute to the impro-.-ement 
of the scientific  basis  needed  by companies  to  improve or develop  their mid-
and long-term competitive capabilities. 
As the technical work develops, dissemination of information about the research 
results  will  commence  - so  providing  new subject-matter which  may  iil  turn 
interest European businesses. 
b.  Employment 
The  effects  on  employment  of the  programme  (inasmuch  as  these  can  be 
measured) are and will  continue to  be of an indirect nature. 26
27 
7.  Consultation of representative organizations 
The Industrial Research and Development Advisoty Committee has been consulted 
during the  preparation of the programme. 27 .  " 
i  ~ 
Specific  research and technological development programme 
in  the field  of Biomedicine and Health 
SUMMARY Ofo  SCIENTIFIC AND TECHNlCAL OBJECTlVES AND CONTENT 
This specific programme fully reflects the approach embodied in the Third Framework 
Programme  in  terms  of the  scientific  and  technical  goals  and  the  underlying  aims 
which it  pursues. 
Paragraph 4C of Annex ([of the Framework Programme forms  an integral part of the 
present specific programme. 
Close  coordination  will  be  maintained  with  other  relevant  research  programmes, 
including 
11
Life sciences and technologies for developing countries", "Telematics Systems 
-Health Care", and "Medical Research" under the European Coal and Steel Community 
Treaty. 
The principle of subsidiarity will be applied to the maximum, through encouraging the 
harmonization  of  approaches  and  methodologies  used  in  different  national 
programmes.  The  projects  themselves  will  have a  European dimension arising from 
their polycentric execution based on research netvvorks. Harmonized methods, specified 
in the relevant protocols, will ensure that the data resulting from  the projects carried 
out throughout the Community, can be statistically analysed and coherently exploited 
anywhere in the Community. 
Prenormative research will  be  developed whenever needed for serving patients' needs 
and for  the completion of the [ntemal Market. 
The content of the programme,  based on and taking account of the above elements, 
covers the following areas: 
Area  1. 
Area  2. 
Area 3. 
Harmonization  of  methodologies  and  protocols  m  epidemiological, 
biological  and clinical  research 
Applications  to diseases of great socio-economic  impact 
Human genome analysis 
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